Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative

PR Newswire — October 17, 2016

INDIANAPOLIS, Oct. 17, 2016 /PRNewswire/ — With the global prevalence of new
cancer cases expected to rise by 70 percent during the next two decades,
representatives from government, academic, pharmaceutical and diagnostic
companies are pooling their knowledge to accelerate treatments to patients.1
Today, Eli Lilly and Company (NYSE: LLY) announced it will contribute cancer
research data to the National Cancer Institute’s Blood Profiling Atlas, an open
access liquid biopsy database being created in response to Vice President Joe
Biden’s call to action and in alignment with the goals of the Cancer Moonshot
initiative. The database is an effort to reduce the development time of
effective and safe blood profiling diagnostic technologies.

“We are honored to be a part of this unique partnership,” said Andrew Schade,
M.D., Ph.D., a distinguished medical fellow in Lilly’s clinical diagnostics
laboratory. “Liquid biopsies are going to be critical in the future to both
identify specific patients for targeted therapies and to follow their treatment
to better determine response to therapy. We hope knowledge gained from our
research efforts in this area will help to accelerate the development of safe
and effective blood profiling diagnostic technologies that help people with

In support of this overarching mission, Lilly is studying approaches for the
profiling of exosomes for mRNA and non-coding RNA expression and will share
sample preparation methods, next-generation quantitative PCR-based methods, and
next generation sequencing-based methods along with data related to disease
characterization through gene expression analysis.

“Our scientists are dedicated to discovering and developing new cancer
treatments to help people living with this disease,” said Jan Lundberg, Ph.D.,
executive vice president of science and technology and president of Lilly
Research Laboratories. “In addition to our own research, external partnerships
are paramount, and we look forward to collaborating with other experts as part
of the Cancer Moonshot initiative.”

The Blood Profiling Atlas is part of the Cancer Moonshot initiative, which was
established to improve the way research is conducted and expedite the delivery
of medicines to patients. Allowing approved researchers access to raw
unprocessed datasets in a scalable and reproducible manner, the open database
will feature the following data: raw data sets from circulating tumor cells,
circulating tumor DNA, and exosome assays, as well as relevant clinical data,
sample preparation, and handling protocols from 12 different studies. The Blood
Profiling Atlas pilot will be curated by a partnership between the University of
Chicago and Seven Bridges, a biomedical data analysis company. For more
information about the Blood Profiling Atlas, please click here.

About Lilly Oncology
For more than 50 years, Lilly has been dedicated to delivering life-changing
medicines and support to people living with cancer and those who care for them.
Lilly is determined to build on this heritage and continue making life better
for all those affected by cancer around the world. To learn more about Lilly’s
commitment to people with cancer, please visit

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make
life better for people around the world. We were founded more than a century ago
by a man committed to creating high-quality medicines that meet real needs, and
today we remain true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to those who need
them, improve the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more about Lilly,
please visit us at and (P-LLY)

Lilly Forward-Looking Statement
This press release contains “forward-looking statements” (as that term is
defined in the United States Private Securities Litigation Reform Act of 1995)
regarding Lilly’s efforts to the National Cancer Institute’s Blood Profiling
Atlas, and reflects Lilly’s current beliefs. However, there are substantial
risks and uncertainties in the process of drug research, development and
commercialization. Among other risks, there can be no guarantee that these
investigational combination regimens will receive regulatory approval, or, if
approved, will achieve intended benefits or become commercially successful. For
further discussion of these and other risks and uncertainties that could cause
actual results to differ materially from Lilly’s expectations, please see the
company’s latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange
Commission. Except as required by law, Lilly undertakes no duty to update
forward-looking statements for events occurring after the date of this release.

1 Cancer. World Health Organization. Accessed October 2016.

Refer to: Media – Amy Sousa;; (317) 997-1481


To view the original version on PR Newswire,

SOURCE Eli Lilly and Company

Subject Codes: PC/t.161017111437581, PT/lang.en, PC/ticker, IN/HEA,
PC/priority.r, PC/category.f, PC/DataFeat_indpr,
PC/DataFeat_natl3, PC/port_32, PC/class.1245,
PC/WAVO_….h., PC/APT_….h, PC/trade_h, PC/wavo5_h,
PC/class.1030, PC/WAVO_l….., PC/APT_l…., PC/state_l,
PC/wavo1_l, PC/class.1254, PC/WAVO_….q., PC/APT_….q,
PC/trade_q, PC/wavo5_q, PC/class.1000, PC/WAVO_..b…,
PC/APT_..b.., PC/circuit_b, PC/wavo3_b, PC/Billing_L85,
PC/Billing_RWB, PC/Billing_TNW, PC/Billing_US1,
PC/1stAcc_916319, PC/OtherAcc_916306, PC/bureau_DE,
PC/port_01, PC/port_96, PC/port_31, PC/port_19,
PC/port_91, PC/photo, PC/id_DE18482

Company Codes: NYSE:LLY

Leave a Reply

Fatal error: Call to undefined function show_subscription_checkbox() in /home3/steer/public_html/ on line 95